AU2011273103B2 - IL-13 producing Tr1-like cells and use thereof - Google Patents

IL-13 producing Tr1-like cells and use thereof Download PDF

Info

Publication number
AU2011273103B2
AU2011273103B2 AU2011273103A AU2011273103A AU2011273103B2 AU 2011273103 B2 AU2011273103 B2 AU 2011273103B2 AU 2011273103 A AU2011273103 A AU 2011273103A AU 2011273103 A AU2011273103 A AU 2011273103A AU 2011273103 B2 AU2011273103 B2 AU 2011273103B2
Authority
AU
Australia
Prior art keywords
cells
producing
human
cell population
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011273103A
Other languages
English (en)
Other versions
AU2011273103A1 (en
Inventor
Herve Bastian
Valerie Brun
Arnaud Foussat
Brigitte Quatannens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics SA
Original Assignee
TxCell SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TxCell SA filed Critical TxCell SA
Publication of AU2011273103A1 publication Critical patent/AU2011273103A1/en
Application granted granted Critical
Publication of AU2011273103B2 publication Critical patent/AU2011273103B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011273103A 2010-06-30 2011-06-30 IL-13 producing Tr1-like cells and use thereof Ceased AU2011273103B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35988510P 2010-06-30 2010-06-30
US61/359,885 2010-06-30
EP10368030A EP2412802A1 (en) 2010-07-29 2010-07-29 IL-13 producing TR1-like cells and use thereof
EP10368030.2 2010-07-29
PCT/IB2011/002269 WO2012001533A2 (en) 2010-06-30 2011-06-30 Il-13 producing tr1-like cells and use thereof

Publications (2)

Publication Number Publication Date
AU2011273103A1 AU2011273103A1 (en) 2013-01-17
AU2011273103B2 true AU2011273103B2 (en) 2015-04-16

Family

ID=43099691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011273103A Ceased AU2011273103B2 (en) 2010-06-30 2011-06-30 IL-13 producing Tr1-like cells and use thereof

Country Status (14)

Country Link
US (1) US20130101568A1 (enExample)
EP (2) EP2412802A1 (enExample)
JP (2) JP2013539356A (enExample)
KR (1) KR20130093083A (enExample)
CN (2) CN107189983A (enExample)
AU (1) AU2011273103B2 (enExample)
BR (1) BR112012033727A2 (enExample)
CA (1) CA2803779A1 (enExample)
CL (1) CL2012003705A1 (enExample)
MX (1) MX347533B (enExample)
NZ (1) NZ605088A (enExample)
RU (1) RU2013103765A (enExample)
WO (1) WO2012001533A2 (enExample)
ZA (1) ZA201209758B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106207A1 (en) * 2017-12-01 2019-06-06 General Electric Company Methods for cell enrichment and isolation
US11920119B2 (en) 2018-02-09 2024-03-05 Global Life Sciences Solutions Usa Llc Systems and methods for bioprocessing
US11932842B2 (en) 2018-02-09 2024-03-19 Global Life Sciences Solutions Usa Llc Bioprocessing apparatus
US12077743B2 (en) 2018-02-09 2024-09-03 Global Life Sciences Solutions Usa Llc Apparatus for fluid line management in a bioprocessing system
US10889792B2 (en) 2018-02-09 2021-01-12 Global Life Sciences Solutions Usa Llc Cell expansion vessel systems and methods
US12252682B2 (en) 2018-02-09 2025-03-18 Global Life Sciences Solutions Usa Llc System and method for fluid flow management in a bioprocessing system
CN113461822B (zh) * 2021-05-21 2022-11-11 深圳市新产业生物医学工程股份有限公司 Scl-70抗体或其结合片段、其筛选方法及包含其的检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP1248643B1 (en) * 2000-01-20 2005-08-17 YEDA RESEARCH AND DEVELOPMENT Co. LTD. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
CN101151275B (zh) * 2005-04-27 2013-07-10 金克克国际有限公司 用于降低细胞因子免疫原性和去除细胞表面标记的方法
US20100034782A1 (en) * 2006-05-31 2010-02-11 Nader Najafian Methods of Using Anti-Thymocyte Globulin and Related Agents
EP2032695B1 (en) * 2006-05-31 2018-08-15 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLAN, S. E. et al., Immunological Reviews, 2008, Vol. 223, pages 391-421 *
BRUN, V. et al., International Immunopharmacology, 2009, Vol. 9, No. 5, pages 609-613 *
BRUSKO, T. M. et al., Immunological Reviews, 2008, Vol. 223, pages 371-390 *
OCHOA-REPARAZ, J., Journal of Immunology, 2008, Vol. 181, No. 2, pages 954-968 *
RONCAROLO, M. G. et al., Immunological Reviews, 2006, Vol. 212, pages 28-50 *

Also Published As

Publication number Publication date
MX2013000115A (es) 2013-09-13
US20130101568A1 (en) 2013-04-25
RU2013103765A (ru) 2014-08-10
CN107189983A (zh) 2017-09-22
NZ605088A (en) 2015-05-29
EP2412802A1 (en) 2012-02-01
JP2013539356A (ja) 2013-10-24
EP2588595A2 (en) 2013-05-08
CL2012003705A1 (es) 2013-12-13
AU2011273103A1 (en) 2013-01-17
WO2012001533A3 (en) 2012-06-07
BR112012033727A2 (pt) 2017-07-18
JP2017148042A (ja) 2017-08-31
CN103080303A (zh) 2013-05-01
CA2803779A1 (en) 2012-01-05
MX347533B (es) 2017-05-02
WO2012001533A2 (en) 2012-01-05
ZA201209758B (en) 2014-03-26
KR20130093083A (ko) 2013-08-21

Similar Documents

Publication Publication Date Title
JP4601166B2 (ja) 抗原特異的ｔ細胞の直接的選択方法
JP7254128B2 (ja) ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
US20150210982A1 (en) Isolation and Use of Human Regulatory T Cells
JP2017148042A (ja) Ｉｌ−１３産生ｔｒ１−様細胞及びその使用
AU2011241892B2 (en) New methods for isolating Tr1 cells
AU2007347364A1 (en) Method for obtaining TREG-cells
RU2766691C9 (ru) НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired